Cervical cancer is the fourth most common cancer worldwide, with over 600,000 new cases
annually and approximately 350,000 cancer-related deaths per year. The disease burden is …

Background Most cervical cancer in the USA occurs in under-screened women. The My
Body, My Test-3 (MBMT-3) trial sought to assess the efficacy of mailed human …

Screening guidelines and practices differ according to resource availability and continually
update as scientific developments take place. In this article, we have reviewed screening …

Cancer screening rates among immigrant and refugee populations in high income countries
is significantly lower than native born populations. The objective of this study is to …

Objectives The addition of p16/Ki-67 dual immunostaining to human papilloma virus (HPV)
screening tests has been shown to increase the detection rate of high-grade cervical …

Background Cervical cancer screening is an important public health priority, yet many
marginalized groups are not reached by existing programs. The nearly 700 million women …

This systematic review evaluates the clinical outcomes and molecular predictors of response
to pembrolizumab in patients with advanced and metastatic cervical cancer. We adhered to …

Background Women with inflammatory bowel disease (IBD) are at increased risk of high‐
grade cervical intraepithelial neoplasia and cervical cancer (CIN2+). Aim To assess the …

Background Cervical cancer is a preventable cancer by screening, vaccination and timely
management of preinvasive cervical lesions. However, about 90% of the global burden of …

Abstract Introduction Persistent Human Papillomavirus (HPV) infection is linked to 99% of
cervical cancer (CC) cases. HPV types 16 and 18 alone result in 75% of CC cases and thus …